Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 
vaccination measured by a point-of-care fingertip whole blood testing

Hagiya, Hideharu; Nakano, Yasuhiro; Furukawa, Masanori; Sunada, Naruhiko; Hasegawa, Toru; Sakurada, Yasue; Hasegawa, Kou; Yamamoto, Koichiro; Ogawa, Hiroko; Obara, Takafumi; Ageta, Kouhei; Matsumoto, Naomi; Matsuo, Rumi; Kadowaki, Tomoka; Higashikage, Akihito; Hikita, Takao; Yorifuji, Takashi; Toyooka, Shinichi; Maeda, Yoshinobu; Yokokura, Yoshinori; Otsuka, Fumio; Nakayama, Akiko

doi:10.1038/s41598-022-24464-3

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing

MPS-Authors

/persons/resource/persons239435

Hikita, Takao
Cell Polarity and Organogenesis, Max Planck Institute for Heart and Lung Research, Max Planck Society;

/persons/resource/persons239386

Nakayama, Akiko
Pharmacology, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Hagiya, H., Nakano, Y., Furukawa, M., Sunada, N., Hasegawa, T., Sakurada, Y., Hasegawa, K., Yamamoto, K., Ogawa, H., Obara, T., Ageta, K., Matsumoto, N., Matsuo, R., Kadowaki, T., Higashikage, A., Hikita, T., Yorifuji, T., Toyooka, S., Maeda, Y., Yokokura, Y., Otsuka, F., & Nakayama, A. (2022). Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing. SCIENTIFIC REPORTS, 12(1):. doi:10.1038/s41598-022-24464-3.

引用: https://hdl.handle.net/21.11116/0000-000D-6642-6

要旨

Amid the Coronavirus Disease 2019 pandemic, we aimed to demonstrate the accuracy of the fingertip whole blood sampling test (FWT) in measuring the antibody titer and uncovering its dynamics shortly after booster vaccination. Mokobio SARS-CoV-2 IgM & IgG Quantum Dot immunoassay (Mokobio Biotechnology R&D Center Inc., MD, USA) was used as a point-of-care FWT in 226 health care workers (HCWs) who had received two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) at least 8 months prior. Each participant tested their antibody titers before and after the third-dose booster up to 14-days. The effect of the booster was observed as early as the fourth day after vaccination, which exceeded the detection limit (>30,000 U/mL) by 2.3% on the fifth day, 12.2% on the sixth day, and 22.5% after the seventh day. Significant positive correlations were observed between the pre- and post-vaccination (the seventh and eighth days) antibody titers (correlation coefficient, 0.405; p<0.001). FWT is useful for examining antibody titers as a point-of-care test. Rapid response of antibody titer started as early as the fourth day post-vaccination, while the presence of weak responders to BNT162b2 vaccine was indicated.